Symbols

WVE

Wave Life Sciences·NASDAQ

--(--)

WVE fundamentals

WVE Q4 2025 Earnings

Wave Life Sciences (WVE) released its earnings on Feb 26, 2026: revenue was 17.24M (YoY -79.41%), beat estimates; EPS was -0.3 (YoY -266.67%), missed estimates.

Revenue / YoY

17.24M

-79.41%

EPS / YoY

-0.3

-266.67%

Report date

Feb 26, 2026

WVE Earnings Call Summary for Q4,2025

Obesity Breakthrough: WVE-007 Phase I data shows fat loss comparable to GLP-1s with muscle preservation. Phase IIa for higher BMI patients to begin H1 2026.
RNA Editing Leadership: WVE-006 AATD program on track for mid-2026 FDA feedback. WVE-008 for PNPLA3 liver disease to enter clinic 2026.
Financial Strength: $602M cash runway supports pipeline through 2028. GSK collaboration drives $2.8B+ potential milestones.
Strategic Differentiation: Unique SpiNA design enables once/twice yearly dosing for WVE-007. RNA editing avoids DNA edits, targeting root cause of AATD.

Earnings

EPS

Revenue

Revenue & Expenses

WVE has released its 2025 Q4 earnings report, with revenue of 17.25M, reflecting a YoY change of -79.41%, and net profit of -53.18M, showing a YoY change of -281.79%. The Sankey diagram below clearly presents WVE's revenue sources and cost distribution.

Key Indicators

Wave Life Sciences (WVE) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Wave Life Sciences (WVE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Wave Life Sciences (WVE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Wave Life Sciences (WVE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown